1-chloro-3-(dipropylamino)propane | 39743-36-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-chloro-3-(dipropylamino)propane
• 英文别名: (3-chloro-propyl)-dipropyl-amine；(3-Chlor-propyl)-dipropyl-amin；1-Chlor-3-dipropylamino-propan；3-Dipropylamino-propylchlorid；Dipropylaminopropyl chloride；3-chloro-N,N-dipropylpropan-1-amine
• CAS: 39743-36-7
• 化学式: C₉H₂₀ClN
• 分子量: 177.717
• InChiKey: FKXYUGSJUMXROI-UHFFFAOYSA-N

物化性质

• 沸点：
  97-105 °C(Press: 25 Torr)
• 密度：
  0.907±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-chloro-3-(dipropylamino)propane 、 二苯基羟基乙酸 在 异丙醇 作用下， 生成 benzilic acid-(3-dipropylamino-propylester); hydrochloride
  参考文献：
  名称：

  Synthetic Mydriatics. III

  摘要：

  DOI：

  10.1021/ja01250a045
• 作为产物：
  描述：

  二正丙胺 在 氯化亚砜 、 氯仿 作用下， 生成 1-chloro-3-(dipropylamino)propane
  参考文献：
  名称：

  Derivatives of 6-Methoxy-8-aminoquinoline and 2-Methyl-6-methoxy-8-aminoquinoline. I

  摘要：

  DOI：

  10.1021/ja01238a009

文献信息

• A novel class of calcium-entry blockers: the 1-[[4-(aminoalkoxy)phenyl]sulfonyl]indolizines
  作者：Jean Gubin、Jean Lucchetti、Jean Mahaux、Dino Nisato、Gilbert Rosseels、Martine Clinet、Peter Polster、Pierre Chatelain

  DOI：10.1021/jm00084a002

  日期：1992.3

  an isopropyl or cyclopropyl group at the 2 position of the indolizine are among the most potent calcium antagonists known outside the 1,4-dihydropyridine series. The IC50 values for the inhibition of [3H]nitrendipine binding vary between 0.19 and 4.5 nM whereas the IC50 value for nifedipine is 2.5 nM. One of the compounds in this group (9ab) has now been selected for clinical development.

  描述了一系列1-磺酰林多嗪的合成和初步生物学评估。这些化合物已被证明是一类新型的有效的慢通道钙拮抗剂。发现所有化合物的活性至少与参考钙拮抗剂维拉帕米和顺-（+）-地尔硫卓相同。结构-活性关系研究表明，所有在胺部分具有芳烷基基团和在吲哚嗪的2位上具有异丙基或环丙基基团的化合物都是1,4-二氢吡啶系列以外已知最有效的钙拮抗剂。抑制[3H]硝苯地平结合的IC50值在0.19至4.5 nM之间变化，而硝苯地平的IC50值为2.5 nM。现在已选择该组中的一种化合物（9ab）用于临床开发。
• Dialkylaminoalkoxybenzylalcohol derivatives, process for their
  申请人：Richter Gedeon Vegyeszeti Gyar Rt

  公开号：US04645779A1

  公开（公告）日：1987-02-24

  The invention relates to new dialkylaminoalkoxybenzylalcohol derivatives of the formula (I) ##STR1## wherein R.sub.1 is hydrogen, halogen, trihalomethyl, alkyl having from one to 4 carbon atoms or alkoxy having from one to 4 carbon atoms; R.sub.2 is halogen, trihalomethyl, alkyl having from one to 4 carbon atoms or alkoxy having from one to 4 carbon atoms; R.sub.3 and R.sub.4 independently stand for an alkyl group having from 3 to 5 carbon atoms; and n is 2, 3, 4 or 5, and acid addition and quanernary ammonium salts thereof. According to another aspect of the invention there are provided processes for the preparation of these compounds. The new compounds provided by the invention are pharmaceutically active, in particular, they are suitable for the treatment of acute ethanolic intoxication. Pharmaceutical compositions containing them as active ingredient are another aspect of the invention.

  本发明涉及公式（I）的新的二烷氨基烷氧基苄醇衍生物 其中，R1是氢、卤素、三卤甲基、具有1至4个碳原子的烷基或具有1至4个碳原子的烷氧基；R2是卤素、三卤甲基、具有1至4个碳原子的烷基或具有1至4个碳原子的烷氧基；R3和R4分别代表具有3至5个碳原子的烷基；n为2、3、4或5，以及它们的酸加成物和季铵盐。根据本发明的另一方面，提供了制备这些化合物的方法。本发明提供的新化合物在药理上具有活性，特别是它们适用于治疗急性乙醇中毒。包含它们作为活性成分的制药组合物是本发明的另一个方面。
• 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
  申请人：——

  公开号：US20030105098A1

  公开（公告）日：2003-06-05

  The present invention comprises 6-9-Disubstituted 2-[trans-(4-aminocyclohexyl]aminopurines that are useful in inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.

  本发明涉及6-9-二取代的2- [转-（4-氨基环己基）]氨基嘌呤，其在抑制细胞周期依赖性激酶，特别是cdk-2方面具有用途。本发明还提供了一种预防神经细胞凋亡和抑制肿瘤发展的方法。
• S-triazolo-1,5-benzodiazpine-4-ones
  申请人：The Upjohn Company

  公开号：US04075202A1

  公开（公告）日：1978-02-21

  A s-triazolo-1,5-benzodiazepin-4-one selected from the group of compounds of the formulae: ##STR1## wherein R.sub.o is hydrogen, alkyl of 1 to 3 carbon atoms, inclusive, hydroxy, hydroxymethyl, and ##STR2## in which R" and R'" are hydrogen or alkyl defined as above, or together ##STR3## is selected from the group consisting of pyrrolidino, piperidino, morpholino, and N-methylpiperazino; wherein R is hydrogen, alkyl of 1 to 3 carbon atoms, inclusive and ##STR4## in which R" and R'" are hydrogen or alkyl as defined above or together ##STR5## is defined as above; wherein R.sub.1 is hydrogen or methyl; wherein R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are selected from the group consisting of hydrogen, alkyl alkyl defined as above, halogen, nitro, trifluoromethyl, and alkylthio in which alkyl is defined as above are produced from the corresponding 4-hydrazino-2H-1,5-benzodiazepines-2-ones of the formula (11A) ##STR6## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 have the significance of above, with an acetic acid chloride or if R.sub.o is hydrogen with ethyl ortho-formate, and heating to an elevated temperature to give the corresponding 4H-s-triazolo[4,3-a][1,5]benzodiazepin-5(6H)-one which by additional procedures can be converted to the various compounds presented by formula 111A. Compounds of formula 111B are best obtained by reacting a 4-thio-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione (1A) ##STR7## with a selected carbazate, followed by heating to an elevated level. Additional steps are necessary to synthesize the various compounds presented by formula 111B. The new compounds of formula 111A and 111B have tranquilizing and sedative activity.

  从下列式中选择一种s-三唑并[1,5]苯二氮平-4-酮化合物：##STR1##其中R.sub.o为氢、1至3个碳原子的烷基、羟基、羟甲基和##STR2##其中R"和R'"为氢或上述定义的烷基，或者一起##STR3##从吡咯烷基、哌啶基、吗啉基和N-甲基哌嗪基中选择；其中R为氢、1至3个碳原子的烷基和##STR4##其中R"和R'"为上述定义的氢或烷基，或者一起##STR5##如上所述定义；其中R.sub.1为氢或甲基；其中R.sub.2、R.sub.3、R.sub.4和R.sub.5从氢、上述定义的烷基、卤素、硝基、三氟甲基和硫代烷基中选择，其中烷基如上所述，由相应的式(11A)的4-肼基-2H-1,5-苯并二氮平-2-酮##STR6##其中R.sub.1、R.sub.2、R.sub.3、R.sub.4和R.sub.5具有上述意义，与乙酸氯或如果R.sub.o为氢，则与乙酸乙酯酸酐反应，并加热至高温，以得到相应的4H-s-三唑并[4,3-a][1,5]苯并二氮平-5(6H)-酮，通过其他步骤可以将其转化为公式111A所示的各种化合物。公式111B的化合物最好是通过将4-硫代-1H-1,5-苯并二氮平-2,4-(3H,5H)-二酮(1A)##STR7##与选择的卡巴肼反应，然后加热至高温来获得的。需要其他步骤来合成公式111B所示的各种化合物。公式111A和111B的新化合物具有镇静和催眠作用。
• POLYSACCHARIDE DERIVATIVE/MAGNETIC METAL OXIDE COMPOSITE
  申请人：MEITO SANGYO KABUSHIKI KAISHA

  公开号：EP0928809A1

  公开（公告）日：1999-07-14

  The present invention provides a polysaccharide-magnetic metal oxide complex consisting of a polysaccharide derivative obtained by carboxyalkyl-etherifying and unsubstituted or substituted aminoalkyl-etherifying a polysaccharide (the above carboxy group and/or amino group may be of a salt form) and a magnetic metal oxide. The above complex has a slow blood clearance and a low toxicity and is useful as a nuclear magnetic resonance imaging contrast medium.

  本发明提供了一种多糖-磁性金属氧化物复合物，由羧基烷基醚化和未取代或取代氨基烷基醚化多糖（上述羧基和/或氨基可以是盐形式）得到的多糖衍生物和磁性金属氧化物组成。上述复合物的血液清除速度慢，毒性低，可用作核磁共振成像造影剂。